Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021
Geneva, Switzerland, May 3, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Q1 2021 financial results on Wednesday May 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and the media on Wednesday, May 5, 2021 at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT).
Title: Addex to Announce Q1 2021 Financial Results
Joining the Conference Call:
2: Provide the Operator with the Participation Pin Code: 64754025#
About Addex Therapeutics:
Forward Looking Statements:
Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as required by law.
Making the Most of Your Teams Investment
Digital Transformation Post COVID-19: Raising the Bar on Customer Engagement